Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Outer membrane acinetobactin receptor (BauA) is a TonB-dependent protein that serves as the primary gateway for the uptake of the siderophore acinetobactin in the Gram-negative pathogen Acinetobacter baumannii (1, 9). Iron is an essential micronutrient for bacterial proliferation, and because the human host actively sequesters iron to restrict pathogen growth, A. baumannii secretes acinetobactin to scavenge it from host proteins like transferrin and lactoferrin (5, 14, 16). The resulting ferric-acinetobactin complex is recognized with high affinity by BauA and transported across the outer membrane into the periplasm, a process essential for the bacterium's survival and virulence in the host (1, 2, 4). Due to its critical role in pathogenesis and its high conservation across multidrug-resistant clinical isolates, BauA is a major target for novel antimicrobial strategies (3, 7). Drug development efforts utilize a "Trojan horse" approach where antibiotics, such as the approved siderophore-cephalosporin Cefiderocol or various experimental conjugates, are chemically linked to siderophore-like moieties to hijack the BauA and related iron-uptake systems for entry (2, 8, 12, 13). Furthermore, BauA is actively being investigated as a potential vaccine candidate, with studies demonstrating that immunization can elicit protective antibodies and reduce bacterial load in murine sepsis models (3, 15).
Siderophore-mediated active transport (Trojan horse strategy) which exploits bacterial iron uptake systems to deliver antimicrobial agents directly into the periplasm or cytoplasm; potential inhibition of iron acquisition through receptor neutralization.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Outer membrane acinetobactin receptor (BauA) (BauA).